CD33 and neoplasm: Next, we treated tumor-bearing mice with AdFITC-CAR T-cells and either 12.5 μg CD117 or CD33 Db-FM as monotherapies or a combination of both adaptors for three weeks starting from seven days after MOLM14-CD117highGFP+Luc+ injection (Fig. 7D).